Although the short- and medium-term (5-10 years) outcome of patients with l
upus nephritis has been studied extensively, there are very few data on the
second and subsequent decades. We studied outcome in 110 local patients in
vestigated at a single centre before 1986, who all had potential follow-up
of more than 10 years (actual 2-31 years, median 15.5 years). At last follo
w-up, 40 patients were dead and 70 alive, nine of whom were on maintenance
dialysis or transplanted, actuarial survivals being 84%, 72%, 62%, 61% and
54% at 5, 10, 15, 20 and 25 years for the group as a whole. Survival was be
tter in the cohort 1976-86 (n=60) than in that from 1963-75 (n=50) (90, 81
and 76% vs. 78, 56 and 43% at 5, 10 and 15 years, p<0.001). Sepsis (12) and
myocardial infarction (8) were the principal causes of death. Of living pa
tients with renal function, 38% had normal urine and renal function, 11 wer
e off all treatment (19%), 62% had persistent proteinuria and 18% had reduc
ed but generally stable renal function, penal failure, in those patients wh
o developed it, occurred during the first decade and none of 67 patients ac
tually followed more than 10 years subsequently went into renal failure. in
duction treatment was with prednisolone, combined with azathioprine in more
severe forms of nephritis, and from the middle 1970s to 1986, 30 with meth
ylprednisolone and in 12 cases plasma exchange. Seventeen other patients we
re treated using oral cyclophosphamide during the 1960s. No patient receive
d i.v. cyctophosphamide as induction therapy, although nine patients had th
is form of treatment later, largely because of non-compliance. Serious comp
lications of lupus and/or its treatment occurred in 49%: sepsis in 32, isch
aemic heart disease in 20, thrombosis in one and avascular necrosis of bone
in eight. In contrast, fracturing osteoporosis occurred in only three, and
cataracts requiring surgery and diabetes mellitus in none. The very long-t
erm outlook of lupus nephritis, especially its more severe forms, has impro
ved, but that with current management strategies only a minority of patient
s are able to stop treatment altogether, and the incidence of serious compl
ications is high.